Science1 distinct publisher3 min readPublished
Boyce Thompson Institute researchers report that ascaroside 18 leaves defense genes easier to switch on, and that field sprays cut fungal disease in corn and soybean. Three of the four named leads co-founded the startup behind it.
The Scientist · Science desk
Compiled by The ScientistSomething wrong?How this is made
The broad-spectrum part of this story is older than the paper. The lab's earlier work already reported that recognition of ascr#18 gave plants a slightly heightened state of immune vigilance and raised resistance to bacterial, viral, fungal and nematode pathogens [5]. What the new work adds is a mechanism and a field demonstration [7][8], which are two different kinds of evidence and should be graded separately.
The mechanism is the more satisfying half. Priming, as Uwe Conrath of RWTH Aachen describes it, works at the chromatin level: defense genes are left more accessible to the transcriptional machinery, so they fire faster once infection arrives [7]. That is a coherent explanation for the economics Dan Klessig describes, in which a full immune response diverts energy from growth while ascr#18 treatment did not show that cost [6]. Worth reading precisely: not observing a growth penalty under the conditions tested is a weaker statement than the absence of one, and the account does not say which growth measurements were taken or for how long.
The field result is where an operator should slow down. Foliar application reduced fungal disease severity and improved yield in corn and soybean [8]. The announcement gives no magnitude for either effect, no number of trial sites, and no number of seasons [15]. Priming accelerates a response the plant would eventually mount anyway; whether a faster response holds up under the inoculum pressure that sends a grower to a fungicide in the first place is exactly what a severity number would answer, and there is not one here.
The seed soak is the genuinely interesting operational claim. Soaking seed in ascr#18 solution was sufficient to prime plants for enhanced defense later in development, unlike treatments that have to land shortly before or during an attack [9]. That moves the decision off the spray calendar and onto the seed invoice, which is a different budget line and a different logistics problem.
Three of the four named research leads, Klessig, Frank Schroeder and Murli Manohar, co-founded the BTI startup Ascribe Bioscience [3], or 75 percent of the named leadership [14]. That is ordinary in translational plant science and it is disclosed. It also means Manohar's emphasis on ease of use and affordability [12] is a company position rather than a measured cost, and that the framing figure of up to 40 percent of global food crops lost annually [10] belongs to the problem statement, not to this study's results.
My read: the chromatin priming mechanism is the durable contribution, and I would treat the corn and soybean field claim as provisional until severity numbers, plot counts and a season run by people without equity are on the table.
Ranked by verification strength, evidence, and original report placement.
Klessig said a full plant immune response carries a fitness cost because energy shifts from growth and development to fighting the pathogen, and that with ascr#18 treatment the team did not see that; instead ascr#18 signals plants to get ready, giving immune memory without the fitness cost.
The report states that plant pathogens can have devastating effects on crop yields, with up to 40% of global food crops lost annually.
A study published in Communications Biology by scientists at the Boyce Thompson Institute found that a previously unrecognized natural compound, the nematode pheromone ascaroside 18 (ascr#18), can provide lasting protection against a broad range of plant pathogens.
The research was led by BTI professor emeritus Dan Klessig and professor Frank Schroeder with former BTI postdoc Murli Manohar, together with Uwe Conrath, professor at RWTH Aachen University in Germany.
Klessig, Schroeder and Manohar are all co-founders of the BTI startup Ascribe Bioscience.
Nematodes, which are ubiquitous in soil and include many plant and animal parasites, produce simple glycolipids called ascarosides.
Distinct publishers with included, body-backed reporting in this cluster.
phys.org
1 article · August 27, 2026
Follow any of these and your For You feed starts watching them — no settings page required.
science
Flow control gets a shared benchmark, and a 38% friction cut nobody had to simulate first2 distinct publishers
product
amber's 7mn-euro bet: the AI cost centre has moved upstream of the model1 distinct publisher
invest
Met Office puts the Pacific 3C above normal, and puts 2027 into next year's budget1 distinct publisher
science
Transport cost, not tonnage: Finnish team remaps who can actually reach the calories1 distinct publisher
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
Peer-reviewed mechanism, single press-release account
The core mechanism claim rests on a named, DOI-identified paper in Communications Biology, which is real evidentiary weight. But the cluster contains only the originating institution's announcement: the field results in corn and soybean are stated without effect sizes, site counts or seasons; the breadth, no-fitness-cost and cost claims are qualitative quotes; and no independent source corroborates any of it.
No adoption signal supplied
The supplied material contains no product release, commercial availability, pricing, licensing, acreage or customer disclosure. The existence of a startup founded by the researchers is noted, but nothing in the cluster shows the compound being deployed, sold or used outside the research program, so no adoption level can be measured.
Promotional framing ahead of disclosed data
The announcement pairs a genuine peer-reviewed mechanism with sweeping applied claims — broad-spectrum protection, works on virtually any crop, inexpensive, needs less material than commercial products, accessible to the average farmer — that carry no numbers, no named comparators and no independent check. The overstatement is moderate rather than severe because the underlying publication and the qualitative field observation are real.
Strong founder-commercial alignment
Three of the four named research leads co-founded Ascribe Bioscience, the BTI startup positioned to commercialize the compound, and those same co-founders supply the quotes about need, breadth, ease and affordability. The only cluster item is the originating institution's own announcement, which has a promotional function. This is a clear, disclosed-but-unexamined incentive to present the compound favorably.
Moderate-low
Confidence is limited by single-publisher, single-source coverage of an institutional announcement, absent quantitative field data and with a strong founder incentive. It is not lower because the underlying study is named, peer-reviewed and DOI-identified, the personnel and affiliations are explicit, and the conflict of interest is disclosed on the record.